HCWB News & Events

HCW Biologics announced major development regarding its tetra-valent, second-generation T-Cell Engager Program based on its TRBC platform technology, which was presented at the poster session at the American Association of Cancer Research Annual Meeting 2026. "HCW11-018b exhibits remarkable anti-tumor activities with high tolerability in animal models. With its streamlined GMP manufacturing process, the Company is vigorously -pursuing the clinical development path for solid tumors with particular focus on pancreatic and ovarian cancer. The IND application is projected to be filed in the first half of 2027," said Hing Wong, founder and CEO.

HCW Biologics announced the receipt of full payment of the upfront license fee with a value of $7M from its licensee, Beijing Trimmune Biotech. Trimmune is a new operating entity responsible for the development and commercialization of HCW11-006, which was formed by WY Biotech and the Company. Trimmune investors include CITIC Medical Fund, a multi-billion-dollar investment fund focused on innovative companies primarily targeting pharmaceuticals, biotechnology, medical devices, and diagnostics, and TigerYeah Capital Fund of TigerMed, a global leading Contract Research Organization. The upfront license fee included a cash fee of $3.5M and a minority co-founder transferable equity position in Trimmune valued at $3.5M based on the most recent round of financing with third parties. HCW Biologics is also eligible to receive significant development milestone payments and double-digit royalties on future product sales, as well as a portion of the proceeds from future transaction involving the licensed molecule, if such a transaction occurs. In addition HCW Biologics has a payment-free, milestone-free, and royalty-free option to recapture all rights to the development and commercialization of HCW11-006 for in vivo applications in the United States, Canada, Central America, and South America after the conclusion of the Phase 1 clinical trial in China. Trimmune is responsible for all costs associated with the Phase 1 clinical trial in China. The deal also provides Trimmune an option to license the exclusive regional China rights to manufacture, develop and commercialize HCW9302, HCW Biologics' clinical stage molecule currently being evaluated in an autoimmune disorder. HCW Biologics is entitled to receive additional payments if Trimmune exercises its option to license HCW9302 for regional China rights.

HCW Biologics "announced results of groundbreaking research studies, published in the peer-reviewed, high-impact journal, Science Advances. These studies were led by Harris Goldstein, M.D., professor of pediatrics and of microbiology & immunology and director of the Einstein-Rockefeller-CUNY-Mount Sinai Center for AIDS Research and his team of Albert Einstein College of Medicine scientists, most notably Erin Cole, M.S., a graduate student in the Goldstein laboratory. The study results demonstrated that HCW9206, the Company's proprietary and commercial-stage multi-cytokine fusion protein reagent, provides a revolutionary approach to generate chimeric T-cell receptor - T cells for immunotherapy with increased function in a cost-effective manner. HCW9206, a first-in-class cytokine-scaffold-based platform, enables production of more potent CAR-T-based immunotherapies by generating a CAR-T population which is highly functional and markedly enriched for long-live T-memory stem cells (Tscm). Utilizing HCW9206 as a manufacturing strategy may be broadly applicable to increase persistence and functionality of CAR-Ts."